TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double Blind, Randomized, Placebo Controlled, Study for Assessment of Dietary Flaxseed on Improving Symptoms of Cardiovascular Disease in Patients With Peripheral Arterial Disease
Brief Summary: This Clinical Trial is being conducted to study how patients with peripheral arterial disease (a condition in which the blood vessels of the extremities are affected) respond to a dietary regimen of flaxseed. The purpose of the study is to examine whether or not dietary flaxseed have any effect on improving symptoms of cardiovascular disease. Additionally, the effects of dietary flaxseed on exercise tolerance will be assessed.


Options:
A: Arm Label: Lutein/Zeaxanthin; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lutein/zeaxanthin | Arm Label: DHA/EPA; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: DHA/EPA | Arm Label: Lutein/Zeaxanthin + DHA/EPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lutein/zeaxanthin and DHA/EPA | Arm Label: Placebo/Control; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Lutein/zeaxanthin; Assigned to Arm(s): Lutein/Zeaxanthin | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA/EPA; Assigned to Arm(s): DHA/EPA | Intervention Type: DRUG; Name: Lutein/zeaxanthin and DHA/EPA; Assigned to Arm(s): Lutein/Zeaxanthin + DHA/EPA
B: Arm Label: n-3 PUFAs; Type: ACTIVE_COMPARATOR; Interventions: Drug: n-3 PUFAs, Drug: RASS inhibitors and/or RAS blockers, Drug: Amiodarone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: RASS inhibitors and/or RAS blockers, Drug: Amiodarone | Intervention Type: DRUG; Name: n-3 PUFAs; Assigned to Arm(s): n-3 PUFAs | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: RASS inhibitors and/or RAS blockers; Assigned to Arm(s): n-3 PUFAs, placebo | Intervention Type: DRUG; Name: Amiodarone; Assigned to Arm(s): n-3 PUFAs, placebo
C: Arm Label: Walnut group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Walnuts | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: habitual diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Walnuts; Assigned to Arm(s): Walnut group | Intervention Type: OTHER; Name: habitual diet; Assigned to Arm(s): Control group
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Flaxseed; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Flaxseed | Intervention Type: DIETARY_SUPPLEMENT; Name: Flaxseed; Assigned to Arm(s): Flaxseed | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double Blind, Randomized, Placebo Controlled, Study for Assessment of Dietary Flaxseed on Improving Symptoms of Cardiovascular Disease in Patients With Peripheral Arterial Disease
Brief Summary: This Clinical Trial is being conducted to study how patients with peripheral arterial disease (a condition in which the blood vessels of the extremities are affected) respond to a dietary regimen of flaxseed. The purpose of the study is to examine whether or not dietary flaxseed have any effect on improving symptoms of cardiovascular disease. Additionally, the effects of dietary flaxseed on exercise tolerance will be assessed.


Options:
A: Arm Label: n-3 PUFAs; Type: ACTIVE_COMPARATOR; Interventions: Drug: n-3 PUFAs, Drug: RASS inhibitors and/or RAS blockers, Drug: Amiodarone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: RASS inhibitors and/or RAS blockers, Drug: Amiodarone | Intervention Type: DRUG; Name: n-3 PUFAs; Assigned to Arm(s): n-3 PUFAs | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: RASS inhibitors and/or RAS blockers; Assigned to Arm(s): n-3 PUFAs, placebo | Intervention Type: DRUG; Name: Amiodarone; Assigned to Arm(s): n-3 PUFAs, placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Flaxseed; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Flaxseed | Intervention Type: DIETARY_SUPPLEMENT; Name: Flaxseed; Assigned to Arm(s): Flaxseed | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Omega 3 (n-3 PUFA) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega 3 (n-3 PUFA); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Safflower oil; Type: EXPERIMENTAL; Interventions: Other: Safflower oil | Arm Label: Control group (no diet instruction); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Safflower oil; Assigned to Arm(s): Safflower oil

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double Blind, Randomized, Placebo Controlled, Study for Assessment of Dietary Flaxseed on Improving Symptoms of Cardiovascular Disease in Patients With Peripheral Arterial Disease
Brief Summary: This Clinical Trial is being conducted to study how patients with peripheral arterial disease (a condition in which the blood vessels of the extremities are affected) respond to a dietary regimen of flaxseed. The purpose of the study is to examine whether or not dietary flaxseed have any effect on improving symptoms of cardiovascular disease. Additionally, the effects of dietary flaxseed on exercise tolerance will be assessed.


Options:
A: Intervention Type: PROCEDURE; Name: Supplementation with fish oil versus placebo; Assigned to Arm(s): N/A
B: Arm Label: Fish oil; Type: EXPERIMENTAL; Interventions: Drug: Fish oil | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Fish oil; Assigned to Arm(s): Fish oil
C: Arm Label: Lower fat diet; Type: EXPERIMENTAL; Interventions: Behavioral: Weight loss | Arm Label: Lower carbohydrate diet; Type: EXPERIMENTAL; Interventions: Behavioral: Weight loss | Arm Label: Walnut-rich diet; Type: EXPERIMENTAL; Interventions: Behavioral: Weight loss | Intervention Type: BEHAVIORAL; Name: Weight loss; Assigned to Arm(s): Lower carbohydrate diet, Lower fat diet, Walnut-rich diet
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Flaxseed; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Flaxseed | Intervention Type: DIETARY_SUPPLEMENT; Name: Flaxseed; Assigned to Arm(s): Flaxseed | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double Blind, Randomized, Placebo Controlled, Study for Assessment of Dietary Flaxseed on Improving Symptoms of Cardiovascular Disease in Patients With Peripheral Arterial Disease
Brief Summary: This Clinical Trial is being conducted to study how patients with peripheral arterial disease (a condition in which the blood vessels of the extremities are affected) respond to a dietary regimen of flaxseed. The purpose of the study is to examine whether or not dietary flaxseed have any effect on improving symptoms of cardiovascular disease. Additionally, the effects of dietary flaxseed on exercise tolerance will be assessed.


Options:
A: Arm Label: Safflower oil; Type: EXPERIMENTAL; Interventions: Other: Safflower oil | Arm Label: Control group (no diet instruction); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Safflower oil; Assigned to Arm(s): Safflower oil
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Flaxseed; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Flaxseed | Intervention Type: DIETARY_SUPPLEMENT; Name: Flaxseed; Assigned to Arm(s): Flaxseed | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Omega 3 recipient arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omega 3 Fish Oil supplements | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Omega 3 Fish Oil supplements; Assigned to Arm(s): Omega 3 recipient arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: BEHAVIORAL; Name: ascorbic acid, vitamin E, beta carotene, selenium, zinc; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double Blind, Randomized, Placebo Controlled, Study for Assessment of Dietary Flaxseed on Improving Symptoms of Cardiovascular Disease in Patients With Peripheral Arterial Disease
Brief Summary: This Clinical Trial is being conducted to study how patients with peripheral arterial disease (a condition in which the blood vessels of the extremities are affected) respond to a dietary regimen of flaxseed. The purpose of the study is to examine whether or not dietary flaxseed have any effect on improving symptoms of cardiovascular disease. Additionally, the effects of dietary flaxseed on exercise tolerance will be assessed.


Options:
A: Arm Label: n-3 PUFAs; Type: ACTIVE_COMPARATOR; Interventions: Drug: n-3 PUFAs, Drug: RASS inhibitors and/or RAS blockers, Drug: Amiodarone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: RASS inhibitors and/or RAS blockers, Drug: Amiodarone | Intervention Type: DRUG; Name: n-3 PUFAs; Assigned to Arm(s): n-3 PUFAs | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: RASS inhibitors and/or RAS blockers; Assigned to Arm(s): n-3 PUFAs, placebo | Intervention Type: DRUG; Name: Amiodarone; Assigned to Arm(s): n-3 PUFAs, placebo
B: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Lovaza (Omega 3 ethyl esters); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Omega 3 acid ethyl esters | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega 3 acid ethyl esters; Assigned to Arm(s): Lovaza (Omega 3 ethyl esters)
C: Intervention Type: DRUG; Name: Triomar™ (omega-3 fatty acids); Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Flaxseed; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Flaxseed | Intervention Type: DIETARY_SUPPLEMENT; Name: Flaxseed; Assigned to Arm(s): Flaxseed | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1, Randomized, Double-Blind, Ascending Multiple-Dose Study of the Safety, Tolerability, and Antiviral Activity of ANA598 in Patients With Chronic Hepatitis C Infection
Brief Summary: The purpose of this study is to investigate the safety, tolerability, and antiviral activity of ANA598 in patients with genotype-1 chronic hepatitis C infection.


Options:
A: Arm Label: SOF/VEL 12 Weeks; Type: EXPERIMENTAL; Interventions: Drug: SOF/VEL | Arm Label: SOF+RBV 24 Weeks; Type: EXPERIMENTAL; Interventions: Drug: SOF, Drug: RBV | Intervention Type: DRUG; Name: SOF/VEL; Assigned to Arm(s): SOF/VEL 12 Weeks | Intervention Type: DRUG; Name: SOF; Assigned to Arm(s): SOF+RBV 24 Weeks | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): SOF+RBV 24 Weeks
B: Arm Label: Sofosbuvir 200 mg (Genotype 1); Type: EXPERIMENTAL; Interventions: Drug: Sofosbuvir, Drug: Placebo to match sofosbuvir, Drug: PEG, Drug: RBV | Arm Label: Sofosbuvir 400 mg (Genotype 1); Type: EXPERIMENTAL; Interventions: Drug: PEG, Drug: RBV | Arm Label: Placebo (Genotype 1); Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo to match sofosbuvir, Drug: PEG, Drug: RBV | Arm Label: Sofosbuvir 400 mg (Genotype 2/3); Type: EXPERIMENTAL; Interventions: Drug: Sofosbuvir, Drug: PEG, Drug: RBV | Intervention Type: DRUG; Name: Sofosbuvir; Assigned to Arm(s): Sofosbuvir 200 mg (Genotype 1), Sofosbuvir 400 mg (Genotype 2/3) | Intervention Type: DRUG; Name: Placebo to match sofosbuvir; Assigned to Arm(s): Placebo (Genotype 1), Sofosbuvir 200 mg (Genotype 1) | Intervention Type: DRUG; Name: PEG; Assigned to Arm(s): Placebo (Genotype 1), Sofosbuvir 200 mg (Genotype 1), Sofosbuvir 400 mg (Genotype 1), Sofosbuvir 400 mg (Genotype 2/3) | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): Placebo (Genotype 1), Sofosbuvir 200 mg (Genotype 1), Sofosbuvir 400 mg (Genotype 1), Sofosbuvir 400 mg (Genotype 2/3)
C: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: ANA598 200 mg bid or placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: ANA598 400 mg bid or placebo | Arm Label: Cohort 3; Type: EXPERIMENTAL; Interventions: Drug: ANA598 800 mg bid or placebo | Intervention Type: DRUG; Name: ANA598 200 mg bid or placebo; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: ANA598 400 mg bid or placebo; Assigned to Arm(s): Cohort 2 | Intervention Type: DRUG; Name: ANA598 800 mg bid or placebo; Assigned to Arm(s): Cohort 3
D: Arm Label: TMC435; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: Peginterferon alpha-2a (PegIFN alpha-2a), Drug: Ribavirin (RBV) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Peginterferon alpha-2a (PegIFN alpha-2a), Drug: Ribavirin (RBV) | Intervention Type: DRUG; Name: TMC435; Assigned to Arm(s): TMC435 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Peginterferon alpha-2a (PegIFN alpha-2a); Assigned to Arm(s): Placebo, TMC435 | Intervention Type: DRUG; Name: Ribavirin (RBV); Assigned to Arm(s): Placebo, TMC435

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The aim of this study is to compare laparoscopic versus open approach on the surgical treatment of mid and low-lying rectal cancer, both performed by the same surgical team with experience in open colorectal surgery and advanced laparoscopic surgery, assessing preoperative and anatomopathological results and long-term outcome.


Options:
A: Arm Label: OPEN SURGERY; Type: ACTIVE_COMPARATOR; Interventions: Procedure: RECTAL CANCER RESECTION | Arm Label: LAPAROSCOPIC SURGERY; Type: EXPERIMENTAL; Interventions: Procedure: RECTAL CANCER RESECTION | Intervention Type: PROCEDURE; Name: RECTAL CANCER RESECTION; Assigned to Arm(s): LAPAROSCOPIC SURGERY, OPEN SURGERY
B: Arm Label: 1; Type: OTHER; Interventions: Procedure: surgery | Intervention Type: PROCEDURE; Name: surgery; Assigned to Arm(s): 1
C: Intervention Type: PROCEDURE; Name: Laparoscopic surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Conventional surgery; Assigned to Arm(s): N/A
D: Arm Label: open rectal resection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: open rectal resection | Arm Label: laparoscopic rectal resection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: laparoscopic rectal resection | Intervention Type: PROCEDURE; Name: open rectal resection; Assigned to Arm(s): open rectal resection | Intervention Type: PROCEDURE; Name: laparoscopic rectal resection; Assigned to Arm(s): laparoscopic rectal resection

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle Following Cataract Surgery in Diabetic Retinopathy Patients
Brief Summary: The purpose of this study is to determine whether nepafenac is safe and effective for reducing the incidence of macular edema following cataract surgery in diabetic retinopathy patients.


Options:
A: Arm Label: NEVANAC; Type: EXPERIMENTAL; Interventions: Drug: Nepafenac ophthalmic suspension, 0.1% (NEVANAC), Drug: Prednisolone acetate ophthalmic suspension (OMNIPRED) | Arm Label: Nepafenac Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Other: Nepafenac ophthalmic suspension vehicle, Drug: Prednisolone acetate ophthalmic suspension (OMNIPRED) | Intervention Type: DRUG; Name: Nepafenac ophthalmic suspension, 0.1% (NEVANAC); Assigned to Arm(s): NEVANAC | Intervention Type: OTHER; Name: Nepafenac ophthalmic suspension vehicle; Assigned to Arm(s): Nepafenac Vehicle | Intervention Type: DRUG; Name: Prednisolone acetate ophthalmic suspension (OMNIPRED); Assigned to Arm(s): NEVANAC, Nepafenac Vehicle
B: Intervention Type: DRUG; Name: Ketorolac, Prednisolone Acetate; Assigned to Arm(s): N/A
C: Arm Label: Nepafenac; Type: EXPERIMENTAL; Interventions: Drug: Nepafenac | Arm Label: Ketorolac; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ketorolac | Intervention Type: DRUG; Name: Nepafenac; Assigned to Arm(s): Nepafenac | Intervention Type: DRUG; Name: Ketorolac; Assigned to Arm(s): Ketorolac
D: Arm Label: NEVANAC; Type: EXPERIMENTAL; Interventions: Drug: Nepafenac ophthalmic suspension, 0.1% (NEVANAC®) | Arm Label: Nepafenac Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nepafenac ophthalmic suspension vehicle | Intervention Type: DRUG; Name: Nepafenac ophthalmic suspension, 0.1% (NEVANAC®); Assigned to Arm(s): NEVANAC | Intervention Type: DRUG; Name: Nepafenac ophthalmic suspension vehicle; Assigned to Arm(s): Nepafenac Vehicle

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Educational and Exercise Program as Secondary Prevention of Recurrent Lower Back Pain in Healthcare Workers: A Randomized, Controlled, 2-year Follow-up Study.
Brief Summary: At Lyon University Medical Center, back problems are the leading cause of sick leave. The course of lower back pain is usually relatively short (recovery occurs within 4 to 6 weeks in 90% of cases). However, about 5-10% develop chronic lower back pain. Although this is a relatively small group, the economic consequences are enormous (accounting for 70 to 80% of the total cost of lower back pain).

Nowadays, some very general training sessions are offered to workers at Lyon University Medical Center, irrespective of their lower back pain status. These very general training sessions are mostly preventive and primary in nature (like back school program) despite the fact that these people already have a history of lower back pain, the main risk factor of recurrence and chronic pain.

Since the 1980, some multidisciplinary functional restoration programs have been advised as a strategy for secondary and tertiary prevention of lower back pain.

The purpose of this randomized controlled trial is to assess the effectiveness of physical exercise combined with an educational program and self-led exercise for Lyon University Medical Center workers with lower back pain. We hope this intervention will reduce the risk of recurrence and chronic lower back pain.


Options:
A: Arm Label: Biopsychosocial; Type: EXPERIMENTAL; Interventions: Behavioral: Biopsychosocial | Arm Label: Reference; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Reference | Intervention Type: BEHAVIORAL; Name: Biopsychosocial; Assigned to Arm(s): Biopsychosocial | Intervention Type: BEHAVIORAL; Name: Reference; Assigned to Arm(s): Reference
B: Arm Label: Treadmill workstation; Type: EXPERIMENTAL; Interventions: Behavioral: Treadmill workstation, Behavioral: Health talk | Arm Label: Control group; Type: EXPERIMENTAL; Interventions: Behavioral: Health talk | Intervention Type: BEHAVIORAL; Name: Treadmill workstation; Assigned to Arm(s): Treadmill workstation | Intervention Type: BEHAVIORAL; Name: Health talk; Assigned to Arm(s): Control group, Treadmill workstation
C: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Intervention | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Other: No intervention | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: No intervention; Assigned to Arm(s): Control
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: educational program, Other: exercise program, Other: Self-led exercises | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: educational program; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: exercise program; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Self-led exercises; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of K-134 for the treatment of intermittent claudication.


Options:
A: Arm Label: Cilostazol + L-Carnitine; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Levocarnitine tartrate, Drug: cilostazol | Arm Label: Cilostazol + Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: cilostazol | Intervention Type: DIETARY_SUPPLEMENT; Name: Levocarnitine tartrate; Assigned to Arm(s): Cilostazol + L-Carnitine | Intervention Type: DRUG; Name: cilostazol; Assigned to Arm(s): Cilostazol + L-Carnitine, Cilostazol + Placebo
B: Arm Label: low dose K-134; Type: EXPERIMENTAL; Interventions: Drug: K-134 | Arm Label: mid dose K-134; Type: EXPERIMENTAL; Interventions: Drug: K-134 | Arm Label: high dose K-134; Type: EXPERIMENTAL; Interventions: Drug: K-134 | Arm Label: Comparator; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cilostazol 100 mg BID | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: K-134; Assigned to Arm(s): high dose K-134, low dose K-134, mid dose K-134 | Intervention Type: DRUG; Name: Cilostazol 100 mg BID; Assigned to Arm(s): Comparator | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Person-centered follow up; Type: EXPERIMENTAL; Interventions: Behavioral: Person-centered follow up | Arm Label: Standard follow up; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Person-centered follow up; Assigned to Arm(s): Person-centered follow up
D: Arm Label: Cilostazol; Type: EXPERIMENTAL; Interventions: Drug: cilostazol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: cilostazol; Assigned to Arm(s): Cilostazol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B